Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN) jumped 16.34% to $4.70 in the pre-market session. The 52 week trading range for TRBN is $1.00 - $6.75. So far in 2009, TRBN gained over 218%.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) moved up 14.29% to $2.40 after Ligand Pharmaceuticals announced new preclinical data on SARM molecule LGD-4033. In the last six months, LGND declined by over 24%. Yesterday, LGND closed at $2.10.
Dyax Corp. (NASDAQ: DYAX) surged 4.25% or $0.15 to $3.80 in the pre-market session. Yesterday, DYAX closed at $3.65. In the last six months, Dyax gained over 60%.
Verigy Ltd. (NASDAQ: VRGY) climbed 11% to $10. Yesterday, VRGY announced that it expects 1Q2010 revenue to be in between $105 to $115 million and loss per share to be in between $0.13 to $0.06. Analysts on an average are expecting VRGY to report loss per share of $0.14 on revenue of $106 million for the first quarter of 2010. VRGY declined by around 6% so far in 2009.
Hibbett Sports, Inc. (NASDAQ: HIBB) increased 5.48% to $20.01 after HIBB raised its earning guidance for the financial year 2010. Yesterday, HIBB closed at $18.97.
Netlist, Inc. (NASDAQ: NLST) moved up 10.93% to $6.29 in the pre-market session. The 52 week trading range for NLST is $0.11 and $6.87. Yesterday, NLST closed at $5.67.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl extended-release) Tablets (CII), (Exalgo) of February 22, 2010.Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer).Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.Genta Incorporated (OTCBB: GETA.OB) announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.Novavax, Inc. (Nasdaq: NVAX) today announced that it has priced an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $3.30 per share.GLG Life Tech Corporation (TSX:GLG)(NASDA:GLGL), the vertically integrated leader in the agricultural and industrial development of high quality stevia extracts, announced today that it has commenced trading on the NASDAQ Global Market under the symbol "GLGL".PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, announced that it has appointed Geoffrey G. Meyers to the Company’s Board of Directors.Cyberonics, Inc. (Nasdaq: CYBX) today announced that Dan Moore, President and Chief Executive Officer, and Greg Browne, Chief Financial Officer, will present at the 21st Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 2, 2009 at 12:00 PM EST.Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.Lannett Company, Inc. (NYSE AMEX: LCI) today announced that its Board of Directors has approved a reauthorization of the stock repurchase program. Under the program the company is authorized to repurchase up to $5 million of Lannett’s outstanding common stock from time to time in open market and privately negotiated transactions.Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m. EST and at the 2009 Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 9:00 a.m. EST.OPTIMIZERx Corporation (OTCBB:OPRX) has engaged Beringea LLC, an investment banking and private equity firm, to assist in financial planning and strategic positioning for the company's continued growth.Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response.Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.Soligenix, Inc. (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
EpiCept Corporation (Nasdaq:EPCT) announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
Allergan, Inc. (NYSE:AGN) announced the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%.
Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Aventis Group, and Keith H. Wells, a senior member of the Biologics Consulting Group and former director of vaccine development for The Salk Institute, to the board.
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced it plans to report third quarter 2009 results on Monday, November 9. SciClone will host a conference call to give a business and product update at 8:30 am ET that day.
EpiCept Corporation (Nasdaq:EPCT) announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.
BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced veteran public company board member and dental executive Gregory D. Waller has been named to its Board of Directors, effective immediately.
Shire plc (NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced an overview of the Company’s business strategy will be presented at the 2009 BIOCOM Investor Conference on Tuesday, October 27, 2009 at 9:30am Pacific Time.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the Company will report third quarter 2009 financial results following the close of the U.S. financial markets on Monday, November 9, 2009.
NanoViricides, Inc. (OTC:NNVC), reports the Company is well financed and its game changing anti-viral drug development programs are progressing successfully.
Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. (NASDAQ:CGEN) project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.
Antigenics (NASDAQ:AGEN) announced the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA. Data were presented in Sunrise Session #6: Immunotherapy: Current Status of Clinical Trials on Saturday, October 24.
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced it plans to report third quarter 2009 results on Monday, November 9.
Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) announced Richard W. Pascoe, Somaxon’s president and chief executive officer, will present a company overview at the Oppenheimer 20th Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Wednesday, November 4th at 4:30 P.M. Eastern Time.
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) announced it has completed its previously announced Registered Direct Offering of common stock and warrants.
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, announced Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET.
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company's TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.
AVI BioPharma, Inc. (NASDAQ:AVII), a developer of RNA-based drugs, presented an update on preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of exon skipping AVI-4658 in patients with Duchenne muscular dystrophy (DMD) at the 7th Annual Action Duchenne Conference in London, UK.
Dyadic International, Inc. (OTC:DYAI) announced financial results for the first and second quarters of 2009 as well as for the years ended December 31, 2008 and 2007.
AMRI (NASDAQ:AMRI) announced it will issue third quarter financial results before the opening of the market on Monday, November 9, 2009. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. EST.
Cannabis Science Inc. (OTC:CBIS) an emerging pharmaceutical cannabis company, is urging that US government recognize that phytocannabinoid pharmaceutical products can help reduce Adult Respiratory Distress Syndrome (ARDS)-associated deaths from both the Avian and Swine Influenza infections, as President Obama declares a national emergency.
Fero Industries, Inc. (OTC:FROI) is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) reported additional data from a Phase 3 study supporting the efficacy of GATTEX™ (teduglutide) in patients with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).
CEL-SCI Corporation (AMEX:CVM) announced it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common stock.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announces the 2009 American College of Gastroenterology (ACG) Annual Scientific Meeting will be the venue for 13 presentations describing the investigation of the Company’s bacterial-related disease, inflammatory bowel disease and bowel cleansing product lines.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced it plans to report third quarter 2009 financial results on Thursday, November 5, 2009, following the close of market.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reviewed recent business and clinical progress and reported consolidated financial results for the quarter ended September 30, 2009.
SuperGen, Inc. (NASDAQ:SUPG) reported financial results for the third quarter and nine months ended September 30, 2009.
Microfluidics International Corporation (OTC:MFLU) announced it has received a $1.0 million secured revolving line of credit from Webster Bank, N.A.
EastBridge Investment Group (OTC:BIG) announced its CEO, Keith Wong, has attended a land acquisition signing ceremony in Jiyuan, Henan for Alpha Green Energy Limited.
Inhibitex, Inc. (NASDAQ: INHX) announced a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference being held at the Waldorf-Astoria Hotel in New York City, New York.
PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.
Ligand Pharmaceuticals Inc., (NASDAQ:LGND) and Metabasis Therapeutics, Inc. (NASDAQ:MBRX) announced they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis.
Geron Corporation (NASDAQ:GERN) will announce its financial results for the 2009 third quarter on Thursday, October 29, 2009, after the closing of the equity market.
Life Technologies Corporation (NASDAQ:LIFE) announced results for its third quarter ended September 30, 2009.
BioSphere Medical, Inc. (NASDAQ:BSMD) – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy –announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.
International Stem Cell Corporation (OTC:ISCO) and Reproductive Medicine Associates of New York (RMA of New York) have show immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived.
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the Company will be presenting at the Oppenheimer 20th Annual Healthcare Conference at 3:55 p.m. EST on November 3, 2009, at the Waldorf Astoria in New York City.
Helicos BioSciences Corporation (NASDAQ:HLCS) announced its operational, technical and scientific highlights for the quarter ended September 30, 2009.
PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.
ImmunoCellular Therapeutics, Ltd. (OTC: IMUC), a biotechnology company which is focused on the development of novel immune-based cancer therapies, announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer 20th Annual Healthcare Conference.
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).
POZEN Inc. (NASDAQ: POZN) announced the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) an immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.
NeoPharm, Inc. (OTC:NEOL) announced it has submitted a Phase II protocol o the FDA for the study of liposome entrapped docetaxel (LE-DT), novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.
OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.
Manhattan Scientifics (OTCBB: MHTX) and Senior Scientific, LLC announced they have begun cooperative work to commercialize Senior Scientific’s nano medicine cancer detection technology.
Inhibitex, Inc. (NASDAQ: INHX) announced it would host a conference call on Friday, November 6, 2009 at 9:00 a.m. EDT to review the Company’s financial results for the third quarter ended September 30, 2009 and provide an update on recent corporate developments.
A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems (OTC:RHHBY) in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.
Revolutions Medical Corporation (OTCBB:RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced CEO Ron Wheet has been featured in the popular AllPennyStocks.com Spotlight series, produced by TheNewsWire.ca.
Rockwell Medical (NASDAQ:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has unveiled a new corporate identity consisting of a new logo, Company name and website.
Unilife Medical Solutions (OTC:UNIFF) announced it has commenced the filing of international trademarks for Unifill™, which will become the market brand for its portfolio of ready-to-fill safety syringes.
Orexigen® Therapeutics, Inc. (Nasdaq:OREX) announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trial of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity.
Cytori Therapeutics, Inc., (NASDAQ:CYTX) will present and provide a webcast of its corporate presentation at the 2009 BIOCOM Investor Conference at 1:00 PM PDT on Tuesday, October 27, 2009.
King Pharmaceuticals, Inc. (NYSE:KG) announced it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.
McKesson Corporation (NYSE:MCK) reported revenues for the second quarter ended September 30, 2009 were $27.1 billion compared to $26.6 billion a year ago.
Please note a change to the Merge Healthcare Inc., (NASDAQ:MRGE) third quarter 2009 earnings call. The call, which was previously scheduled for 4:15 PM EDT on Thursday, October 29, 2009, will now be held at 9:00 AM EDT.
PPD, Inc. (Nasdaq:PPDI) reported its financial and operating results for the third quarter ended September 30, 2009.
Total Nutraceutical Solutions, Inc. (OTC:TNUS), announced the company has formulated and will launch a unique natural whole food mushroom-based Vitamin D supplement.
Osteologix, Inc. (OTC:OLGX) announced Philip J. Young, President and CEO of Osteologix, will present a corporate overview and update at the 8th Annual Bio Investor Forum being held this week at the Palace Hotel in San Francisco, California.
3SBio Inc. (Nasdaq:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009.
TomoTherapy Inc., (NASDAQ:TOMO) announced four recipients of grants from the first round of its 2009-2010 TomoTherapy® Clinical Investigation Partnership Program.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Bristol-Myers Squibb (NYSE:BMY) announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.
ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced it has signed an extension to its strategic agreement with Eli Lilly and Company (NYSE:LLY) to manage the company’s clinical data management outside the US.
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) announced executive management will participate in the Oppenheimer Healthcare Conference to be held November 3 - 4, 2009 at the Waldorf Astoria in New York City.
Arrayit Corporation (OTC:ARYC) is pleased to join the federal government in their efforts to help control health care costs by leveraging Arrayit's leading edge health care platform.
AEterna Zentaris Inc. (Nasdaq:AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.
Perrigo Company (Nasdaq:PRGO) announced it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in Israel to Emilia Group, a subsidiary of O. Feller Holdings Ltd., for 205 million New Israeli Shekels (approximately $54 million).
Vanda Pharmaceuticals Inc., (Nasdaq:VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, announced financial and operational results for the third quarter ended September 30, 2009.
Kinetic Concepts, Inc. (NYSE:KCI) announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted final regulatory approval for KCI to market and sell its innovative V.A.C.® Therapy System in the country.
Cytori Therapeutics Inc. (NASDAQ:CYTX) will release and host a webcast to discuss its third quarter financial results on Monday, November 9, 2009 at 10:30 AM Eastern time.
GTx, Inc. (NASDAQ:GTXI) announced it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
AMRI (NASDAQ:AMRI) announced a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE:BMY) will proceed into preclinical development.
GTC Biotherapeutics, Inc. (NASDAQ:GTCB) announced LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire françaindu Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has exercised its option to purchase $12.8 million of additional convertible preferred stock under the terms described in the financing agreements approved by GTC shareholders in July 2009.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has amended its license agreement with Exelixis, Inc. (NASDAQ:EXEL) as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights.
Gilead Sciences, Inc. (Nasdaq:GILD), in collaboration with GlaxoSmithKline (GSK), announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).
Dendreon Corporation (Nasdaq:DNDN) announced it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE 4; (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA).Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced a contract award to support the FDA’s production rollout of the company’s WebSDM™ Release 3.0 software, including the Empirica™ Study Clinical Trials Signal Detection system.
iMedicor (OTC:VMCI) announced it has received a Scope of Work (SOW) order from its partner, Franklyn Ideas, LLC (Franklyn) on behalf of one of its major pharmaceutical clients.
Walgreens (NYSE:WAG), the nation’s largest drugstore chain with more than 70,000 health service providers, will host its first-ever Diabetes Wellness Events at more than 1,500 stores nationwide in November.
CVS Caremark (NYSE:CVS) announced it has extended its contract to provide retail pharmacy benefit services and all clinical services for the Blue Cross and Blue Shield Government-wide Service Benefit Plan, also known as the Federal Employee Program (FEP).
Herbalife Ltd. (NYSE:HLF) reported third quarter 2009 net sales of $600.2 million, a decrease of 0.3 percent compared to the same period of 2008, primarily reclecting the 780 basis point unfavorable impact from currency fluctuations.
Antares Pharma, Inc. (Amex:AIS) announced it will release its third quarter 2009 financial results after the market closes on Monday, November 9, 2009, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to discuss the results.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced its Special Meeting of Stockholders, which was convened on October 30, 2009, was adjourned to November 6, 2009 at 11:00 a.m., local time, at 4225 Executive Square, Suite 495, La Jolla, California.
Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year. Both the companies had entered the research and license agreement in December 2006 with Wyeth ...
All News |
Breaking News |
Featured Stories